Serum and CSF measles antibody levels increase over time in patients with multiple sclerosis or clinically isolated syndrome

Journal of Neuroimmunology

Volumn 247, Issue 1-2, 2012, Pages 70-74

  Ahlgren, Cecilia ^a   Odén, Anders ^b   Bergström, Tomas ^a   Lycke, Jan ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

Author keywords

CSF; Duration of disease; Epidemiology; Measles virus antibodies; Multiple sclerosis; Polyspecific immune response

Indexed keywords

MEASLES ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CHILD; CONTROLLED STUDY; DEMYELINATING DISEASE; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LYMPHOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PLASMA CELL; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; SCHOOL CHILD;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CHILD; DEMYELINATING DISEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MEASLES; MIDDLE AGED; MULTIPLE SCLEROSIS; TIME FACTORS; YOUNG ADULT;

EID: 84860837489     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.03.014     Document Type: Article

References (28)

1. Adams J.M., Brooks M.B., Fisher E.D., Tyler C.S. Measles antibodies in patients with multiple sclerosis and with other neurological and nonneurological diseases. Neurology 1970, 20(10):1039-1042.
2. Ahlgren C., Oden A., Haghighi S., Andersen O., Bergstrom T., Lycke J. The effect of live, attenuated measles vaccine and measles infection on measles antibody levels in serum and CSF of patients with multiple sclerosis or clinically isolated syndrome. J. Neuroimmunol. 2011, 235(1-2):98-103.
3. Bar-Or A., Calabresi P.A., Arnold D., Markowitz C., Shafer S., Kasper L.H., Waubant E., Gazda S., Fox R.J., Panzara M., Sarkar N., Agarwal S., Smith C.H. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann. Neurol. 2008, 63(3):395-400.
4. Brettschneider J., Tumani H., Kiechle U., Muche R., Richards G., Lehmensiek V., Ludolph A.C., Otto M. IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome. PLoS One 2009, 4(11):e7638.
5. Compston D.A., Vakarelis B.N., Paul E., McDonald W.I., Batchelor J.R., Mims C.A. Viral infection in patients with multiple sclerosis and HLA-DR matched controls. Brain 1986, 109(Pt 2):325-344.
6. Davidkin I., Jokinen S., Broman M., Leinikki P., Peltola H. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J. Infect. Dis. 2008, 197(7):950-956.
7. Forghani B., Schmidt N.J. Antigen requirements, sensitivity, and specificity of enzyme immunoassays for measles and rubella viral antibodies. J. Clin. Microbiol. 1979, 9(6):657-664.
8. Frischer J.M., Bramow S., Dal-Bianco A., Lucchinetti C.F., Rauschka H., Schmidbauer M., Laursen H., Sorensen P.S., Lassmann H. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009, 132(Pt 5):1175-1189.
9. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., Bar-Or A., Panzara M., Sarkar N., Agarwal S., Langer-Gould A., Smith C.H. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 2008, 358(7):676-688.
10. Jacobi C., Lange P., Reiber H. Quantitation of intrathecal antibodies in cerebrospinal fluid of subacute sclerosing panencephalitis, herpes simplex encephalitis and multiple sclerosis: discrimination between microorganism-driven and polyspecific immune response. J. Neuroimmunol. 2007, 187(1-2):139-146.
11. Kappos L., Li D., Calabresi P.A., O'Connor P., Bar-Or A., Barkhof F., Yin M., Leppert D., Glanzman R., Tinbergen J., Hauser S.L. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011, 378(9805):1779-1787.
12. Krugman S. Further-attenuated measles vaccine: characteristics and use. Rev. Infect. Dis. 1983, 5(3):477-481.
13. Levin L.I., Munger K.L., Rubertone M.V., Peck C.A., Lennette E.T., Spiegelman D., Ascherio A. Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 2005, 293(20):2496-2500.
14. Link H., Kostulas V. Utility of isoelectric focusing of cerebrospinal fluid and serum on agarose evaluated for neurological patients. Clin. Chem. 1983, 29(5):810-815.
15. Magliozzi R., Howell O., Vora A., Serafini B., Nicholas R., Puopolo M., Reynolds R., Aloisi F. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007, 130(Pt 4):1089-1104.
16. Magliozzi R., Howell O.W., Reeves C., Roncaroli F., Nicholas R., Serafini B., Aloisi F., Reynolds R. A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann. Neurol. 2010, 68(4):477-493.
17. Panelius M., Salmi A., Halonen P.E., Kivalo E., Rinne U.K., Penttinen K. Virus antibodies in serum specimens from patients with multiple sclerosis, from siblings, and matched controls. A final report. Acta Neurol. Scand. 1973, 49(1):85-107.
18. Petereit H.F., Reske D. Expansion of antibody reactivity in the cerebrospinal fluid of multiple sclerosis patients - follow-up and clinical implications. Cerebrospinal Fluid Res. 2005, 2:3.
19. Prineas J.W. Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord. Science 1979, 203(4385):1123-1125.
20. Prineas J.W., Wright R.G. Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab. Invest. 1978, 38(4):409-421.
21. Reiber H. External quality assessment in clinical neurochemistry: survey of analysis for cerebrospinal fluid (CSF) proteins based on CSF/serum quotients. Clin. Chem. 1995, 41(2):256-263.
22. Reiber H., Lange P. Quantification of virus-specific antibodies in cerebrospinal fluid and serum: sensitive and specific detection of antibody synthesis in brain. Clin. Chem. 1991, 37(7):1153-1160.
23. Reiber H., Ungefehr S., Jacobi C. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult. Scler. 1998, 4(3):111-117.
24. Reiber H., Teut M., Pohl D., Rostasy K.M., Hanefeld F. Paediatric and adult multiple sclerosis: age-related differences and time course of the neuroimmunological response in cerebrospinal fluid. Mult. Scler. 2009, 15(12):1466-1480.
25. Serafini B., Rosicarelli B., Magliozzi R., Stigliano E., Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004, 14(2):164-174.
26. Sundstrom P., Juto P., Wadell G., Hallmans G., Svenningsson A., Nystrom L., Dillner J., Forsgren L. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 2004, 62(12):2277-2282.
27. Tibbling G., Link H., Ohman S. Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand. J. Clin. Lab. Invest. 1977, 37(5):385-390.
28. Zeman D., Adam P., Kalistova H., Sobek O., Andel J., Andel M. Cerebrospinal fluid cytologic findings in multiple sclerosis. A comparison between patient subgroups. Acta Cytol. 2001, 45(1):51-59.